Navigation Links
Nanotechnology holds promise for STD drug delivery
Date:5/3/2009

New Haven, Conn. Yale researchers describe a breakthrough in safe and effective administration of potential antiviral drugs small interfering RNA (siRNA) molecules that silence genes the first step in development of a new kind of treatment for sexually transmitted diseases (STDs). The work is reported May 4 as an advance online publication of Nature Materials.

"RNA interference is a promising approach for prevention and treatment of human disease," said lead author Kim Woodrow, Yale postdoctoral fellow in Yale's School of Engineering & Applied Science. "We wanted to develop a new strategy of delivering siRNAs with a FDA-approved material."

As their name suggests, siRNAs interfere and knock out the function of genes in higher organism as well as in microbes that may cause STDs. The researchers designed siRNAs to target a gene expressed widely in the lining of the female mouse reproductive tract, in this proof-of-principle work.

Using densely-loaded nanoparticles made of a biodegradable polymer known as PLGA, the researchers created a stable "time release" vehicle for delivery of siRNAs to sensitive mucosal tissue like that of the female reproductive system.

They found that the particles, loaded with the drug agent, moved effectively in two important ways, penetrating to reach cells below the surface of the mucosa and distributing throughout the vaginal, cervical, and uterine regions. Furthermore, the siRNAs stayed in the tissues for at least a week and knockdown of gene activity lasted up to 14 days.

While past work has focused on delivery of siRNAs with liposomes, bubble-like carriers made of phospholipids similar to those found in cell membranes, liposomes are potentially more toxic to the mucosal tissues and are unable to provide sustained release. In the current work, the researchers demonstrated that PLGA nanoparticles were safer than the best current lipid vehicles.

Gene interference therapy is moving rapidly from basic research to application. The PLGA packaging these researchers chose is already approved as safe and non-toxic by the FDA, speeding the path to clinical trials for infectious agents such as HPV and HIV.

"Before human clinical testing can begin, our next step in research will be to test this approach directly in disease models for example in the HIV model mice that have an immune system genetically identical to humans," said senior author W. Mark Saltzman, the Goizueta Foundation Professor of Biomedical Engineering & Chemical Engineering.

This approach holds promise for global health and the ability of people to selfapply antimicrobial treatments. Woodrow said, "It is safe and effective and much easier than getting an injection of vaccine."


'/>"/>

Contact: Janet Rettig Emanuel
janet.emanuel@yale.edu
203-432-2157
Yale University
Source:Eurekalert  

Related biology news :

1. Yale scientists use nanotechnology to fight E. coli
2. Nanotechnology: Whats that?
3. Rice University nanotechnology expert to give testimony
4. US government delays nanotechnology safety measures
5. Rice University expert calls for coordination in nanotechnology research
6. NIH recognizes Clemson nanotechnology for molecule tracking
7. Nanotechnology and the media: The inside story
8. Using nanotechnology, UCLA researchers discover cancer cells feel much softer than normal cells
9. FDLI, PEN co-sponsor major conference on nanotechnology
10. Iridescence workshop promotes natures nanotechnology
11. Strategy for nanotechnology-related environmental, health and safety research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nanotechnology holds promise for STD drug delivery
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology: